Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
05 nov. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submissions for AXS-05 in depression expected in January 2021,...